TY  - JOUR
AU  - Santoro, Francesco
AU  - Nunez-Gil, Ivan Javier
AU  - Vitale, Enrica
AU  - Viana-Llamas, Maria C.
AU  - Reche-Martinez, Begona
AU  - Romero-Pareja, Rodolfo
AU  - Feltez Guzman, Gisela
AU  - Fernandez Rozas, Inmaculada
AU  - Uribarri, Aitor
AU  - Becerra-Munoz, Victor Manuel
AU  - Alfonso-Rodriguez, Emilio
AU  - Garcia-Aguado, Marcos
AU  - Huang, Jia
AU  - Ortega-Armas, Maria Elizabeth
AU  - Garcia Prieto, Juan F.
AU  - Corral Rubio, Eva Maria
AU  - Ugo, Fabrizio
AU  - Bianco, Matteo
AU  - Mulet, Alba
AU  - Raposeiras-Roubin, Sergio
AU  - Jativa Mendez, Jorge Luis
AU  - Espejo Paeres, Carolina
AU  - Albarran, Adrian Rodriguez
AU  - Marin, Francisco
AU  - Guerra, Federico
AU  - Akin, Ibrahim
AU  - Cortese, Bernardo
AU  - Ramakrishna, Harish
AU  - Macaya, Carlos
AU  - Fernandez-Ortiz, Antonio
AU  - Brunetti, Natale Daniele
PY  - 2021
DO  - 10.1136/heartjnl-2021-319552
SN  - 1355-6037
UR  - https://hdl.handle.net/10668/26896
T2  - Heart
AB  - Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet...
LA  - en
PB  - Bmj publishing group
KW  - COVID-19
KW  - pharmacology
KW  - clinical
KW  - Coronavirus disease 2019
TI  - Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
TY  - research article
VL  - 108
ER  -